Antimicrobial resistance (AMR) is a growing public health concern and a threat to global health security. 700,000 people die each year from AMR infections, and it is estimated that by 2050, AMR infections could cause 10 million deaths per year1.
Multi-drug resistant (MDR) bacteria are a particular threat as existing antibiotics are becoming ineffective. During this webinar we will explore the challenges and opportunities in developing new interventions to prevent and treat bacterial infections including new antibiotics, vaccines and non-traditional modalities.
So why aren’t (enough) new antibiotics being developed to add to our arsenal? An important reason is that the traditional business model for innovative pharmaceutical products doesn’t apply. If you were to develop a new antibiotic today, it might be shelved to use in case of an emergency only, because introducing new antibiotics might give rise to more resistance and even stronger pathogens. In addition, it is a long, complicated, and risky process to develop new antibiotics. There are other potential barriers. Do our health care systems fully recognize the value of new antibiotics? Are there enough late-stage investments in antibiotic development?
Other innovations might prevent or treat MDR bacterial infections without increasing antibiotic resistance. These interventions include bacterial vaccines and disruptive, non-traditional modalities such as phage and CRISPR. How can we pave the road for their successful development and introduction?
The global community of public and private organizations, non-profits, governments, and life science innovators are rallying around the AMR challenge. Join the discussion as thought leaders share their views on the challenges surrounding this global health threat and the potential solutions. Topics will include:
1. Priority MDR bacterial pathogens of interest
2. Potential interventions to prevent and treat MDR bacterial infections
3. Barriers in the development and commercialization pathway
4. The need for policy change to address these barriers
5. The potential roles of various organizations and public-private partnerships
*This program is part of BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA).